Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States

por Ross, Lisa L., Shortino, Denise, Shaefer, Mark S.
Publicado 2018

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57...

por Small, Catherine Butkus, Margolis, David A., Shaefer, Mark S., Ross, Lisa L.
Publicado 2017

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudi...

por Robertson, Kevin, Maruff, Paul, Ross, Lisa L., Wohl, David, Small, Catherine B, Edelstein, Howard, Shaefer, Mark S.
Publicado 2018

Treatment-Emergent Mutations and Resistance in HIV-Infected Children Treated with Fosamprenavir-Containing Antiretroviral Regimens

por Ross, Lisa L, Cotton, Mark F, Cassim, Haseena, Voronin, Eugeny, Givens, Naomi, Sievers, Jorg, Cheng, Katharine Y
Publicado 2015

No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjects

por Ross, Lisa L., Song, Ivy H., Arya, Niki, Choukour, Mike, Zong, Jian, Huang, Shu-Pang, Eley, Timothy, Wynne, Brian, Buchanan, Ann M.
Publicado 2016

Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks

por Squires, Kathleen E, Young, Benjamin, Santiago, Lizette, Dretler, Robin H, Walmsley, Sharon L, Zhao, Henry H, Pakes, Gary E, Ross, Lisa L, Shaefer, Mark S
Publicado 2017

Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT

por Smith, Kimberly Y, Weinberg, Winkler G, DeJesus, Edwin, Fischl, Margaret A, Liao, Qiming, Ross, Lisa L, Pakes, Gary E, Pappa, Keith A, Lancaster, C Tracey
Publicado 2008

Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial

por Wohl, David A., Bhatti, Laveeza, Small, Catherine B., Edelstein, Howard, Zhao, Henry H., Margolis, David A., DeJesus, Edwin, Weinberg, Winkler G., Ross, Lisa L., Shaefer, Mark S.
Publicado 2014

Pharmacokinetics, Safety and Antiviral Activity of Fosamprenavir/Ritonavir-containing Regimens in HIV-infected Children Aged 4 Weeks to 2 Years—48-week Study Data

por Cotton, Mark, Cassim, Haseena, Pavía-Ruz, Noris, Garges, Harmony P., Perger, Teodora, Ford, Susan L., Wire, Mary Beth, Givens, Naomi, Ross, Lisa L., Lou, Yu, Sievers, Jörg, Cheng, Katharine
Publicado 2014

HIV-1 Transmission Patterns in Antiretroviral Therapy-Naïve, HIV-Infected North Americans Based on Phylogenetic Analysis by Population Level and Ultra-Deep DNA Sequencing

por Ross, Lisa L., Horton, Joseph, Hasan, Samiul, Brown, James R., Murphy, Daniel, DeJesus, Edwin, Potter, Martin, LaMarca, Anthony, Melendez-Rivera, Ivan, Ward, Douglas, Uy, Jonathon, Shaefer, Mark S.
Publicado 2014

Pharmacokinetics and 48-week Safety and Antiviral Activity of Fosamprenavir-containing Regimens in HIV-infected 2- to 18-year-old Children

por Fortuny, Claudia, Duiculescu, Dan, Cheng, Katharine, Garges, Harmony P., Cotton, Mark, Tamarirt, Desamparados Pérez, Ford, Susan L., Wire, Mary Beth, Givens, Naomi, Ross, Lisa L., Lou, Yu, Perger, Teodora, Sievers, Jörg
Publicado 2014

Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretro...

por Ross, Lisa L., Walker, A. Sarah, Lou, Yu, Tenorio, Allan R., Gibb, Diana M., Double, Julia, Gilks, Charles, McCoig, Cynthia C., Munderi, Paula, Musoro, Godfrey, Kityo, Cissy M., Grosskurth, Heiner, Hakim, James, Mugyenyi, Peter N., Cutrell, Amy, Perger, Teodora, Shaefer, Mark S.
Publicado 2019